An investor asked on the investor interaction platform: is your company’s international multi center clinical trial outsourced or self-developed? Does your company have the conditions to carry out international multicenter clinical trials independently?
Jiangsu Hengrui Medicine Co.Ltd(600276) (600276. SH) said on the investor interaction platform on January 20 that self-research and outsourcing are the means for the company to carry out international multi center clinical trials. At present, the company has established a complete clinical R & D team covering medical science, clinical operation, registration, pharmacology, statistics, quality management, pharmacovigilance and other departments in the United States and Europe.
